GEMIFLOXACIN

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H20FN5O4
Molecular Weight	389.3809
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO\N=C1/CN(CC1CN)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=N2)C(O)=O

InChI

InChIKey=ZRCVYEYHRGVLOC-HYARGMPZSA-N

InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27588824 | https://www.ncbi.nlm.nih.gov/pubmed/19684863

Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin mesylate is marketed under the brand name Factive, indicated for the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae. Gemifloxacin has in vitro activity against a wide range of Gram-negative and Grampositive microorganisms. Gemifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs). Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV (TOPO IV), which are essential for bacterial growth. Streptococcus pneumoniae showing mutations in both DNA gyrase and TOPO IV (double mutants) are resistant to most fluoroquinolones. Gemifloxacin has the ability to inhibit both enzyme systems at therapeutically relevant drug levels in S. pneumoniae (dual targeting), and has MIC values that are still in the susceptible range for some of these double mutants.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DNA gyrase 26 Target ID: CHEMBL2094139 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19684863 \| https://www.ncbi.nlm.nih.gov/pubmed/15194123	Inhibitor 8297	500.0 nM [IC50]
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15155113	Inhibitor 8297
Haemophilus influenzae 10 Target ID: CHEMBL355 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15155113	Inhibitor 8297
Topoisomerase IV subunit A 7 Target ID: CHEMBL4088 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16337791	Inhibitor 8297	300.0 nM [IC50]
DNA gyrase 26 Target ID: CHEMBL2311225 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11036032	Inhibitor 8297
Topoisomerase IV 62 Target ID: CHEMBL2363033 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11036032	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic bronchitis 51 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	Curative		Approved 8429	FACTIVE Approved Use Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae. MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 µg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. Launch Date 2003
Community-acquired pneumonia 47 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	Curative		Approved 8429	FACTIVE Approved Use FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES .) Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
1.61 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	320 mg 1 times / day multiple, oral dose: 320 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GEMIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
9.93 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	320 mg 1 times / day multiple, oral dose: 320 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GEMIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	320 mg 1 times / day multiple, oral dose: 320 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GEMIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
35% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	320 mg 1 times / day multiple, oral dose: 320 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GEMIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	Disc. AE: Hepatic enzymes increased, Pneumonia... AEs leading to discontinuation/dose reduction: Hepatic enzymes increased (grade 3-4, 1.8%) Pneumonia (grade 3-4, 0.6%) Diarrhea (grade 3-4, 0.6%) Flatulence (grade 3-4, 0.6%) Intestinal obstruction (grade 3-4, 0.6%) Nausea (grade 3-4, 0.6%) Vomiting (grade 3-4, 0.6%) Aortic stenosis (grade 3-4, 0.6%) Myocardial infarction (grade 3-4, 0.6%) Somnolence (grade 3-4, 0.6%) Pleurisy (grade 3-4, 0.6%) Respiratory insufficiency (grade 3-4, 0.6%) Rash (grade 3-4, 0.6%) Leucocytosis NOS (grade 3-4, 0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185

AEs

AE	Significance	Dose	Population
Aortic stenosis	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Diarrhea	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Flatulence	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Intestinal obstruction	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Leucocytosis NOS	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Myocardial infarction	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Nausea	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Pleurisy	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Pneumonia	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Rash	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Respiratory insufficiency	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Somnolence	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Vomiting	grade 3-4, 0.6% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185
Hepatic enzymes increased	grade 3-4, 1.8% Disc. AE	320 mg 1 times / day multiple, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: multiple Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185	unhealthy, 59.6 n = 172 Health Status: unhealthy Condition: Community-Acquired Pneumonia Age Group: 59.6 Sex: M+F Population Size: 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf Page: Study 185

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 CYP3A4/5 278 CYP4A9/11 37	CYP 450 31 P-gp 1537 MRP2 205 BCRP 561

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no
CYP4A9/11 37	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=35 Page: 35.0	no

Drug as victim

Target	Modality	Activity
CYP 450 31	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P2.pdf#page=4 Page: 4.0	no
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/23020787/	yes
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/23020787/	yes
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195835/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_pharmr_P1.pdf#page=4 Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:101853	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:101853
ChemicalBook	CB3855593	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3855593
eMolecules	27520355	https://www.emolecules.com/cgi-bin/more?vid=27520355

PubMed

Title	Date	PubMed
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.	2000 Sep	10952620
Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.	2001 Apr	11266415
Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation.	2001 Jan-Feb	11347965
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.	2002 Mar	11850285
Fluoroquinolones as chemotherapeutics against mycobacterial infections.	2004	15544510
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.	2004 Apr	15047530
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bronchitis 320 mg orally once a day for 5 days Usual Adult Dose for Pneumonia 320 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

Gemifloxacin demonstrates impressive minimal inhibitory concentrations (MIC 90 ) values against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae and Legionella spp., with MIC 90 values reported to be 0.016-0.06, < 0.0008-0.06, 0.008-0.3, 0.25, 0.125 and 0.016-0.07 ug/ml, respectively.

Name

Type

Language

GEMIFLOXACIN

Official Name

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(3-(AMINOMETHYL)-4-(METHOXYIMINO)-1-PYRROLIDINYL)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4- OXO-

Common Name

English

gemifloxacin [INN]

Common Name

English

7-(3-AMINOMETHYL-4-METHOXYIMINO-PYRROLIDINE-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO-(1,8)-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Systematic Name

English

GEMIFLOXACIN [VANDF]

Common Name

English

(±)-7-(3-(AMINOMETHYL)-4-OXO-1-PYRROLIDINYL)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7(SUP 4)-(Z)-(O)-METHYLOXIME)

Common Name

English

GEMIFLOXACIN [MI]

Common Name

English

FACTIV

Brand Name

English

Gemifloxacin [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000007606